Breaking

How Trump could spare Biden’s renewable energy credits and still cripple his landmark climate bill
A tale of two Syrians: One finally made it back, another is too fearful to return
Trump-backed spending bill goes down in flames as shutdown looms
Crowd crush kills 35 children at funfair in Nigeria, police say
Pakistan denounces US sanctions on its missile program as ‘discriminatory’
Westgold Shares Scoping Study for Expansion of Fortnum Gold Operation
5 Best-performing Canadian Nickel Stocks of 2024
Malls are using new restaurants to draw consumers as shopping centers reinvent themselves

Politics
Business
World
Investing
Search for:

Investing

RAD 202 receives approval to start Phase 1 therapeutic trial

December 20, 2024

Share on Facebook Share on Twitter Pinterest LinkedIn Tumblr Email

Share

Share on Facebook Share on Twitter Pinterest Email

Radiopharm Theranostics (RAD:AU) has announced RAD 202 receives approval to start Phase 1 therapeutic trial

Download the PDF here.

This post appeared first on investingnews.com

0

Related Posts

Westgold Shares Scoping Study for Expansion of Fortnum Gold Operation

December 20, 2024

5 Best-performing Canadian Nickel Stocks of 2024

December 20, 2024

Hempalta Corp. Announces Financial Results for Year Ended September 30, 2024

December 19, 2024

Get free access to all of the retirement secrets and income strategies from our experts! or Join The Exclusive Subscription Today And Get the Premium Articles Acess for Free

Your name

Your email

By opting in you agree to receive emails from us and our affiliates. Your information is secure and your privacy is protected.
Categories
- Business (1,335)
- Investing (3,454)
- Politics (5,120)
- World (4,591)

Disclaimer: payfordesire.com, its managers, its employees, and assigns (collectively “The Company”) do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice. The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.
Latest

Copyright © 2024 payfordesire.com | All Rights Reserved

Top

Politics
Business
World
Investing

Type above and press Enter to search. Press Esc to cancel.